title: Relation between atrial fibrillatory rate and markers of inflammation and haemostasis in persistent human atrial fibrillation.
authors.forename: Arnljot
authors.initials: A
authors.lastname: Tveit
authors.forename: Andreas
authors.initials: A
authors.lastname: Bollmann
authors.forename: Ingebjørg
authors.initials: I
authors.lastname: Seljeflot
authors.forename: Daniela
authors.initials: D
authors.lastname: Husser
authors.forename: Martin
authors.initials: M
authors.lastname: Stridh
authors.forename: Leif
authors.initials: L
authors.lastname: Sörnmo
authors.forename: Harald
authors.initials: H
authors.lastname: Arnesen
authors.forename: S Bertil
authors.initials: SB
authors.lastname: Olsson
authors.forename: Pål
authors.initials: P
authors.lastname: Smith
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000097:blood* / Q000276:immunology* / Q000517:prevention & control; D001562:Benzimidazoles / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood*; D001713:Biphenyl Compounds; D004562:Electrocardiography; D006487:Hemostasis; D006801:Humans; D007249:Inflammation / Q000097:blood; D013777:Tetrazoles / Q000627:therapeutic use
chemical_list: D000959:Antihypertensive Agents; D001562:Benzimidazoles; D015415:Biomarkers; D001713:Biphenyl Compounds; D013777:Tetrazoles; C081643:candesartan